Want to see THC full AI Analyst Report?
THC Stock Chart & Stats
$233.20
$34.18(17.17%)
At close: 4:00 PM EDT
$233.20
$34.18(17.17%)
Day’s Range― - ―
52-Week Range$157.58 - $265.32
Previous CloseN/A
Volume4.64M
Average Volume (3M)1.35M
Market Cap
$20.51B
Enterprise Value$30.83K
Total Cash (Recent Filing)$2.17B
Total Debt (Recent Filing)$13.25B
Price to Earnings (P/E)9.8
Beta1.00
Next Earnings
Nov 03, 2026EPS Estimate
4.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)26.12
Shares Outstanding80,519,000
10 Day Avg. Volume1,714,656
30 Day Avg. Volume1,354,110
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)4.25
Price to Sales (P/S)0.84
P/FCF Ratio7.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$276.20Price Target Upside18.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)20.76
Revenue Forecast (FY)$22.18B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained multi-billion operating and free cash flow provides durable funding for capital expenditures, debt paydown, M&A, and share repurchases. High absolute cash generation enhances financial flexibility and reduces reliance on external financing across economic cycles.
Robust Operating Margins And Revenue GrowthElevated EBIT and net margins coupled with strong trailing revenue growth reflect improved operating efficiency and favorable case mix. These structural margin levels support sustainable profitability from hospital and ambulatory businesses even amid cyclical patient-volume swings.
High‑margin Outpatient (USPI) PlatformA large, high-margin ambulatory surgery footprint aligns with secular outpatient migration and supports durable EBITDA growth. Strong unit economics and same-facility revenue gains enhance cash return potential and provide a scalable M&A runway for accretive acquisitions.
Bears Say
Elevated LeverageMaterial indebtedness limits capital flexibility and raises sensitivity to interest-cost shocks or cash-flow setbacks. While equity has strengthened recently, leverage remains a structural constraint on reinvestment, payouts, and M&A if operating performance weakens.
Regulatory And Reimbursement RiskPotential changes to outpatient payment and drug reimbursement create lasting uncertainty for revenue and margin models. If final rules reduce reimbursements, Tenet's hospital and ASC economics could be structurally impaired, requiring long-term cost or network adjustments.
Payer Mix And Exchange Enrollment DeclinesSustained erosion in exchange enrollment reduces commercially priced volumes and compresses revenue per facility. Geographic concentration of these declines amplifies site-level revenue risk and may necessitate ongoing structural cost actions or strategic market repositioning.
Tenet Healthcare News
THC FAQ
What was Tenet Healthcare’s price range in the past 12 months?
Tenet Healthcare lowest stock price was $157.58 and its highest was $265.31 in the past 12 months.
What is Tenet Healthcare’s market cap?
Tenet Healthcare’s market cap is $20.51B.
When is Tenet Healthcare’s upcoming earnings report date?
Tenet Healthcare’s upcoming earnings report date is Nov 03, 2026 which is in 87 days.
How were Tenet Healthcare’s earnings last quarter?
Tenet Healthcare released its earnings results on Jul 23, 2026. The company reported $6.12 earnings per share for the quarter, beating the consensus estimate of $4.261 by $1.859.
Is Tenet Healthcare overvalued?
According to Wall Street analysts Tenet Healthcare’s price is currently Undervalued.
Does Tenet Healthcare pay dividends?
Tenet Healthcare does not currently pay dividends.
What is Tenet Healthcare’s EPS estimate?
Tenet Healthcare’s EPS estimate is 4.64.
How many shares outstanding does Tenet Healthcare have?
Tenet Healthcare has 80,519,000 shares outstanding.
What happened to Tenet Healthcare’s price movement after its last earnings report?
Tenet Healthcare reported an EPS of $6.12 in its last earnings report, beating expectations of $4.261. Following the earnings report the stock price went up 17.174%.
Which hedge fund is a major shareholder of Tenet Healthcare?
Currently, no hedge funds are holding shares in THC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenet Healthcare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$276.20 (18.44% Upside)
$276.20 (18.44% Upside)
Blogger Sentiment
Bullish
THC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 207.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.89%
Trailing 12-Months
Company Description
Tenet Healthcare
Tenet Healthcare Corporation operates as a broad-ranging provider of health solutions. The company organizes its operations across three main divisions: Hospital Operations and Other, Ambulatory Care, and Conifer. Within its network of acute care facilities, Tenet delivers a full spectrum of essential services. These include core hospital functions such as operating and recovery suites, radiology and respiratory therapy, clinical laboratories, and on-site pharmacies. The organization also provides high-acuity patient care through intensive, critical, and coronary care units. Specialized medical services cover areas like cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics, alongside various outpatient treatments, including physical therapy. Advanced surgical capabilities feature cardiothoracic, complex spinal, and neurosurgery, as well as neonatal intensive care. Tenet extends its offerings to ultra-specialized quaternary care, exemplified by heart and kidney transplant programs, and sophisticated procedures such as limb-salvaging vascular interventions, acute Level 1 trauma care, intravascular stroke treatment, minimally invasive cardiac valve replacements, advanced imaging, and telemedicine access. Beyond its hospital network, Tenet manages numerous other clinical sites. These encompass outpatient surgical centers, immediate care facilities, diagnostic imaging centers, dedicated surgical hospitals, off-campus emergency departments, and micro-hospitals. Through its Conifer segment, the company furnishes critical healthcare business process solutions. These administrative services, offered to hospitals, health systems, physician practices, employers, and other clients, include financial administration for patient accounts (revenue cycle management), support for patient communications and engagement, and outcome-focused care strategies. As of February 9, 2022, Tenet's operational footprint included 60 hospitals and roughly 550 additional medical facilities. This count of additional sites comprises surgical hospitals, ambulatory surgery centers, urgent care and imaging centers, and various other clinical locations. Tenet Healthcare Corporation was established in 1975 and maintains its principal office in Dallas, Texas.
THC Company Deck
THC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid operational and financial outperformance: strong revenue and EBITDA growth, a robust EPS increase, raised full-year guidance, substantial free cash flow, improved leverage and active capital deployment (notably large share repurchases and anticipated USPI M&A). These positives were offset by material payer mix challenges—chiefly a significant decline in exchange enrollment and revenues, localized state impacts, modest ASC case volume weakness, and regulatory/reimbursement uncertainty. Management emphasized that expense actions, technology and clinical improvements and portfolio positioning have thus far mitigated the headwinds and supported an upward revision to guidance.View all THC earnings summariesTHC Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$276.20
▲(18.44% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
1.00% Insiders
31.59% Mutual Funds
2.17% Other Institutional Investors
37.73% Public Companies and
Individual Investors










